MX2020013153A - Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. - Google Patents

Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.

Info

Publication number
MX2020013153A
MX2020013153A MX2020013153A MX2020013153A MX2020013153A MX 2020013153 A MX2020013153 A MX 2020013153A MX 2020013153 A MX2020013153 A MX 2020013153A MX 2020013153 A MX2020013153 A MX 2020013153A MX 2020013153 A MX2020013153 A MX 2020013153A
Authority
MX
Mexico
Prior art keywords
immunity against
protective immunity
compositions
methods
immunodeficiency virus
Prior art date
Application number
MX2020013153A
Other languages
English (en)
Inventor
Dan Barouch
Johanna Schuitemaker
Maria Grazia Pau
Manen Danielle Van
Frank Tomaka
Jennifer Anne Hendriks
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of MX2020013153A publication Critical patent/MX2020013153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Se describen composiciones, vacunas y métodos para inducir inmunidad protectora contra la infección por el Virus de Inmunodeficiencia Humana (VIH); las combinaciones de vacunas heterólogas de uno o más vectores de expresión víricos y un polipéptido antigénico aislado indujeron una fuerte inmunidad protectora frente a infecciones por uno o múltiples clados de VIH.
MX2020013153A 2014-09-26 2017-03-24 Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. MX2020013153A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056059P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
MX2020013153A true MX2020013153A (es) 2021-02-18

Family

ID=55581992

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003946A MX2017003946A (es) 2014-09-26 2015-09-24 Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
MX2020013153A MX2020013153A (es) 2014-09-26 2017-03-24 Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017003946A MX2017003946A (es) 2014-09-26 2015-09-24 Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.

Country Status (28)

Country Link
US (4) US10137191B2 (es)
EP (2) EP3197489B1 (es)
JP (2) JP6438575B2 (es)
KR (2) KR101971808B1 (es)
CN (2) CN112121160A (es)
AP (1) AP2017009846A0 (es)
AU (2) AU2015320574B2 (es)
BR (1) BR112017005917A2 (es)
CA (1) CA2961024A1 (es)
CY (1) CY1124254T1 (es)
DK (1) DK3197489T3 (es)
EA (2) EA202092521A1 (es)
ES (1) ES2865150T3 (es)
HR (1) HRP20210608T1 (es)
HU (1) HUE053585T2 (es)
IL (2) IL251114B (es)
LT (1) LT3197489T (es)
MA (1) MA40765B1 (es)
MX (2) MX2017003946A (es)
MY (1) MY175620A (es)
PH (1) PH12017500449A1 (es)
PL (1) PL3197489T3 (es)
PT (1) PT3197489T (es)
RS (1) RS61902B1 (es)
SG (1) SG11201702110RA (es)
SI (1) SI3197489T1 (es)
WO (1) WO2016049287A1 (es)
ZA (1) ZA201702053B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101971808B1 (ko) 2014-09-26 2019-04-23 베쓰 이스라엘 디코니스 메디칼 센터 인크 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
SG10202109457RA (en) 2015-12-15 2021-10-28 Janssen Vaccines & Prevention Bv Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CA3014419A1 (en) 2016-02-16 2017-08-24 Geovax Inc. Multivalent hiv vaccine boost compositions and methods of use
CA3027454A1 (en) 2016-06-16 2017-12-21 Janssen Vaccines & Prevention B.V. Hiv vaccine formulation
JP2019526580A (ja) * 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
LT3512543T (lt) 2016-09-15 2020-11-10 Janssen Vaccines & Prevention B.V. Trimerą stabilizuojančios živ apvalkalo baltymo mutacijos
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
MA49616A (fr) 2017-07-19 2020-05-27 Janssen Vaccines & Prevention Bv Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en) * 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
AU2019345942A1 (en) 2018-09-25 2021-03-18 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020214203A1 (en) * 2019-04-17 2020-10-22 The Wistar Institute Replication deficient adenoviral vectors for hiv vaccine applications
TW202110476A (zh) * 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
EP3972642A1 (en) * 2019-05-22 2022-03-30 Aelix Therapeutics S.L. Dosage regimens for vaccines
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3159907A1 (en) * 2019-11-07 2021-05-14 Janssen Vaccines & Prevention B.V. Protein purification
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
WO2003048184A2 (en) 2001-12-04 2003-06-12 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
CA2880061C (en) 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
WO2006002079A2 (en) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
EP1789438B1 (en) 2004-08-27 2015-04-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant MVA viruses expressing modified env, gag and pol genes from HIV clade A/G, clade B, and clade C
EA010433B1 (ru) 2004-10-13 2008-08-29 Круселл Холланд Б.В. Усовершенствованные аденовирусные векторы и их применение
CN101072585A (zh) * 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
WO2007005934A2 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
CA2655934A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
EP2073840A4 (en) 2006-10-23 2010-10-27 Progenics Pharm Inc MODIFIED GP140 ENVELOPE POLYPEPTIDES FROM HIV-1 ISOLATES, COMPOSITIONS, TRIMERIC COMPLEXES AND USES THEREOF
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
SI3335728T1 (sl) 2008-10-10 2020-04-30 Children's Medical Center Corporation Biokemično stabilizirano HIV-1 ENV trimer cepivo
CN102282175B (zh) 2008-11-18 2015-09-30 贝斯以色列护理医疗中心 具有改进的细胞免疫原性的抗病毒疫苗
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CN105399833B (zh) 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
US8859257B2 (en) 2010-01-28 2014-10-14 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of MVA
EP2536829B1 (en) * 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
SI3556396T1 (sl) 2010-08-31 2022-09-30 Theraclone Sciences, Inc. Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
CA2813685A1 (en) 2010-10-15 2012-04-19 Josef Weigl Recombinant modified vaccinia virus ankara influenza vaccine
CN103370411B (zh) 2010-12-14 2016-05-04 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
CN105263506B (zh) 2013-01-07 2018-03-09 贝丝以色列女执事医疗中心 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
KR101971808B1 (ko) * 2014-09-26 2019-04-23 베쓰 이스라엘 디코니스 메디칼 센터 인크 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SG10202109457RA (en) 2015-12-15 2021-10-28 Janssen Vaccines & Prevention Bv Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
JP2019526580A (ja) * 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法

Also Published As

Publication number Publication date
WO2016049287A1 (en) 2016-03-31
US20200030437A1 (en) 2020-01-30
ES2865150T3 (es) 2021-10-15
EA037583B1 (ru) 2021-04-16
CN106999571A (zh) 2017-08-01
CN106999571B (zh) 2020-10-02
AP2017009846A0 (en) 2017-03-31
BR112017005917A2 (pt) 2017-12-12
AU2018267669A1 (en) 2018-12-13
EP3197489A1 (en) 2017-08-02
MA40765A (fr) 2017-08-02
SI3197489T1 (sl) 2021-08-31
IL251114B (en) 2019-05-30
US10137191B2 (en) 2018-11-27
US20220096622A1 (en) 2022-03-31
IL265733A (en) 2019-05-30
CY1124254T1 (el) 2022-07-22
KR101971808B1 (ko) 2019-04-23
IL251114A0 (en) 2017-04-30
AU2015320574B2 (en) 2018-12-06
MX2017003946A (es) 2017-12-20
RS61902B1 (sr) 2021-06-30
AU2018267669B2 (en) 2020-03-05
HUE053585T2 (hu) 2021-07-28
US20160089432A1 (en) 2016-03-31
JP2019038849A (ja) 2019-03-14
CN112121160A (zh) 2020-12-25
EA202092521A1 (ru) 2021-05-31
EP3197489A4 (en) 2018-03-14
KR102159626B1 (ko) 2020-09-25
PL3197489T3 (pl) 2021-11-08
DK3197489T3 (da) 2021-04-19
US10471137B2 (en) 2019-11-12
CA2961024A1 (en) 2016-03-31
NZ730841A (en) 2021-08-27
US11207400B2 (en) 2021-12-28
KR20170066454A (ko) 2017-06-14
MY175620A (en) 2020-07-02
JP6438575B2 (ja) 2018-12-12
US20180250385A1 (en) 2018-09-06
JP6625716B2 (ja) 2019-12-25
ZA201702053B (en) 2021-09-29
HRP20210608T1 (hr) 2021-06-11
KR20190042736A (ko) 2019-04-24
AU2015320574A1 (en) 2017-04-06
EP3197489B1 (en) 2021-02-17
LT3197489T (lt) 2021-07-26
PT3197489T (pt) 2021-04-30
SG11201702110RA (en) 2017-04-27
MA40765B1 (fr) 2021-04-30
JP2017531627A (ja) 2017-10-26
IL265733B (en) 2021-05-31
EP3868398A1 (en) 2021-08-25
EA201790717A1 (ru) 2018-02-28
PH12017500449A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
WO2015134368A3 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
MY183072A (en) Methods and compositions for inducing protective immunity against filovirus infection
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2018013340A (es) Combinaciones de vacunas terapeuticas para el vph.
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
WO2016100926A8 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
MX2018008529A (es) Virus de la tilapia de tipo ortomixo.
EP3526236A4 (en) SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
PH12019500903A1 (en) Isolation of a novel pestivirus causing congenital tremor a
EP3303370A4 (en) T20 CONSTRUCTION PRODUCTS FOR THERAPY AND / OR ANTI-HIV VACCINES (HUMAN IMMUNODEFICIENCY VIRUS)
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
EP3382012A4 (en) LIVE VIRUS COMPRISING A BANK OF DENGUE-VIRUS-DENGED STRAINS, AND DENGUE VACCINE CONTAINING THE DENGUE AS ANTIGENS
PE20212213A1 (es) Cepas de vbi y usos de las mismas
TH1501003876A (th) วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน